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Cost-Effectiveness Analysis of Somatostatin Analogues
in the Treatment of Acromegaly in Brazil
ABSTRACT
This study aims to compare economic and patient impacts of the treatment of 
acromegaly with two different somatostatin analogues (octreotide LAR and lan-
reotide SR) in Brazil. A cost-effectiveness analysis was carried out under the Bra-
zilian Public Health Care System (SUS) perspective. A decision analytical model 
was developed based on the Brazilian Public Health Care System Clinical Guide-
line for Acromegaly. A hypothetical cohort of 276 patients was followed for two 
years. Data were extracted from literature and administrative databases. Based 
on the analytical model, treatment with octreotide LAR would avoid 12 and 17 
cases of GH and IGF-I elevated serum levels, respectively. Octreotide LAR was a 
cost-saving strategy,  with net savings of R$10,448,324 (US$4,465,096) to SUS. 
Annual net savings per patient were R$ 18,928 (US$8,089). Treatment of acro-
megaly with octreotide LAR is a dominant strategy when compared to the treat-
ment with lanreotide SR in Brazil. Sensitivity analysis did not alter the cost-saving 
status. (Arq Bras Endocrinol Metab 2008; 52/9:1452-1460)
Keywords: Cost effectiveness; Acromegaly; Somatostatin analogues; Oct-
reotide; Lanreotide
RESUMO
Análise de Custo-Efetividade de Análogos da Somatostatina no Tratamento 
de Acromegalia no Brasil.
O objetivo deste estudo é comparar o impacto econômico e o impacto nos 
pacientes com acromegalia do tratamento com dois diferentes análogos de 
somatostatina (octreotida LAR e lanreotide SR) no Brasil. Um estudo de custo-
efetividade foi realizado a partir da perspectiva do Sistema Único de Saúde 
(SUS). Foi desenvolvido um modelo analítico de decisão baseado no Protocolo 
Clínico e Diretrizes Terapêuticas de Acromegalia do SUS. Uma coorte hipoté-
tica de 276 pacientes foi seguida por dois anos. Dados foram obtidos da litera-
tura e bases de dados ofi ciais do SUS. Baseado no modelo analítico, o 
tratamento com octreotida LAR evitaria 12 e 17 casos com níveis elevados de 
GH e IGF-I, respectivamente. Octreotida LAR foi uma estratégia econômica, 
gerando economia de R$10.448.324 (US$4.465.096) para o SUS. A economia 
anual por paciente foi de R$18.928 (US$8.089). O tratamento de acromegalia 
com octreotida LAR é estratégia dominante quando comparado com o trata-
mento com lanreotida SR no Brasil. A análise de sensibilidade não alterou seu 
status de econômica. (Arq Bras Endocrinol Metab 2008; 52/9:1452-1460)
Descritores: Custo-efetividade; Acromegalia; Análogo de somatostatina; Oct-
reotida; Lanreotida.
INTRODUCTION 
Acromegaly is a rare chronic endocrine disease caused by growth hormo-ne (GH) hypersecretion. A pituitary somatotroph adenoma is the sour-
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ce of this hypersecretion in more than 95% of the 
cases. GH stimulates hepatic production of insulin-li-
ke growth factor-I (IGF-I). Some somatic effects are 
directly produced by GH, while others are mediated 
by IGF-I (1). The annual incidence of this disease is 
3-4 cases per million with a prevalence of 40-70 cases 
per million (2-3). The disease presents the same fre-
quency for men and women and its mean age of onset 
is estimated to be 30-50 years (2-4). Due to its slowly 
progressive nature, formal diagnosis often occurs 10 
years after the fi rst symptoms and signs appear (4). 
Complications associated to acromegaly are cardio-
vascular, respiratory and neoplasic diseases, that con-
tribute to the increased mortality rate related to this 
disease, which is 2-4 times higher than that of an age 
and sex matched population (4-5). Adequate treat-
ment, as well as early diagnosis, may revert the increa-
sed mortality risk in acromegalic patients. There are 
no epidemiological studies of the Brazilian population 
on acromegalic patients (4). 
Diagnosis includes clinical assessment; laboratory 
tests (measures of GH, IGF-I levels and GH evaluation 
during the oral glucose tolerance test); MRI or CT 
scan; and histopathologic assessment when patient un-
dergoes surgery (4).
Management of acromegaly is complex and pre-
sents many treatment options. Surgery is the primary 
treatment option. The rate of success in transsphenoi-
dal surgery (TS) depends on the experience and ability 
of the neurosurgeon, on the tumor size and extension 
and on the pre-surgery GH level. Over 30% of tumors 
are microadenomas and 70% macroadenomas (6). Re-
mission rate post-surgery is over 70-80% in patients 
with microadenomas and less than 50% in patients har-
boring macroadenomas, in the hands of experienced 
surgeons (7-8). Surgical expertise is defi ned as trai-
ning experience of more than 100 pituitary surgeries 
cases and annual surgical activity of more than 25 ca-
ses/year (9-11). 
Medical treatment options are somatostatin analo-
gues, octreotide [Octreotide has two presentations: 
subcutaneous (sc), daily injection, and depot (Long-
Acting Release - LAR), whose administration occurs 
every 28 days] LAR (Sandostatin® LAR, Novartis) and 
lanreotide [Lanreotide has two formulations: SR (Slow 
Release), a depot presentation administered every 14 
days (interval which can be reduced to 7 days) and Au-
togel, a deep subcutaneous injection, administered 
every 28 days] SR (Somatuline® LA, Ipsen); dopamine 
agonists, bromocriptine (Parlodel®, Novartis) and ca-
bergoline (Dostinex®, Pfi zer). A novel approach is the 
receptor antagonist, pegvisomant (Somavert®, Pfi zer). 
Radiotherapy is a third-line treatment whose modalities 
are conventional radiotherapy, available throughout 
the Brazilian Healthcare System, and radiosurgery, res-
tricted to some reference centers (4).
In 2002, the Brazilian Public Health Care System 
(SUS) released a Clinical Guideline for Acromegaly. 
The drug class of somatostatin analogues became avai-
lable in the Brazilian Public Healthcare System for the 
treatment of patients with acromegaly (12). Regarding 
dopamine agonists, cabergoline also became available 
in 2002 whereas bromocriptine was already on SUS 
drug list. Octreotide subcutaneous and LAR, bromo-
criptine and cabergoline are on the list of “Exceptional 
Drugs”, one of the programs of free-of-charge drug 
dispensation provided by SUS. Lanreotide SR was also 
available until 2006. 
Considering the medical treatment options availa-
ble in SUS, our objective is to perform a cost-effective-
ness analysis (CEA) of acromegaly treatment with 
somatostatin analogues under the Public Health Care 
System perspective (SUS), in order to compare diffe-
rent strategies of treatment, based on the Brazilian 
Guideline (12). Economic evaluation studies of acro-
megaly are rare in the literature (13,14), and there is no 
study applied to Brazil. 
METHODS 
Model and Clinical Parameters
The treatment algorithm of Acromegaly outlined by 
the Brazilian Public Health Care System Clinical Gui-
deline for Acromegaly (12) indicates the use of soma-
tostatin analogues, for patients with macroadenomas or 
microadenomas who have not presented controlled 
GH levels after transsphenoidal surgery and patients 
with invasive macroadenomas, not surgically remova-
ble. Based on this algorithm, treatment with somatos-
tatin analogues should last initially three months in case 
of depot presentation. Evaluating the patient after three 
months would determine the physician conduct: conti-
nue the somatostatin analogue when GH level is con-
trolled or increase its dose in case of a high GH level . 
If GH level is not controlled after dose increase of ei-
ther octreotide LAR or lanreotide SR, the medical tre-
atment should be substituted by a dopamine agonist. If 
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still not responding (high GH level) the physician 
should consider association of somatostatin analogue 
and dopamine agonist or reconsider surgery and/or ra-
diotherapy.
Based on the Brazilian Guideline for the treatment 
of Acromegaly (12) above described, a decision analyti-
cal model was developed in Microsoft Excel. The deci-
sion tree is presented in Figure 1.
The initial strategies compare the treatments with 
two somatostatin analogues: 1) Treatment with octre-
otide LAR; 2) Treatment with lanreotide SR (Lanreo-
tide Autogel was not included as a strategy in this 
model. The product and its price is not available in SUS 
drug list. Furthermore there is a lack of robust scientifi c 
data on the literature regarding tumor reduction and 
its comparison to other drugs).
Time horizon was established in two years, accor-
ding to what had been done in the literature (13). Two 
years is suffi cient to assess if the patient will respond to 
somatostatin analogue or not.
The model followed the sequence of possible treat-
ment options set by the Guideline (12), applying an 
initial three-month period in the new treatment, when 
it has to be changed (in the case of high GH levels). 
According to that period and to the treatment sequen-
ces, patients going to radiotherapy would stay on this 
treatment for a year. Control of hormone levels usually 
begins after a period of six months until two years after 
starting radiotherapy (15). In a study in the United 
Kingdom, it was shown that hormone levels were con-
trolled after two years (16). The late response to radio-
therapy implies, in this model, that patients in the 
radiotherapy branch are not assessed to GH level con-
trol. Radiotherapy technique in the model is the linear 
accelerator. The treatment would happen in 25 frac-
tions in three different fi elds.
The outcomes considered in the analysis were bio-
chemical effi cacy endpoints, cases of elevated GH and 
IGF-I avoided, and life years saved (LYS). Although 
normalization of GH level is the only criteria presented 
in the Brazilian Guideline (12), control of IGF-I level 
was also considered in the analysis to refl ect the clinical 
practice (17). As there is no consensus in the literature 
about the use of IGF-I as a predictor of long-term ou-
tcome (17), mortality reduction was related only to 
normalization of GH level in the model.
The Brazilian Guideline establishes as controlled GH 
levels values < 2 ng/mL (12). In the present study, based 
on the last consensus (9) values below 2.5 ng/mL were 
considered as controlled GH levels. Furthermore it is 
also in accordance to the values that were used in a meta-
analysis of long-acting somatostatin analogues therapy in 
acromegaly, in which effi cacy endpoint was defi ned as 
GH level < 2,5 ng/mL in most of the studies evaluated 
(18). In this meta-analysis (18) octreotide LAR and lan-
reotide SR are the second therapy after transsphenoidal 
surgery and/or radiotherapy and octreotide sc. The per-
centage of patients with no previous treatment was too 
low and as a consequence they were assessed along with 
the patients in the secondary treatment. 
In the base case scenario, according to Freda and 
cols. (18), for GH control octreotide LAR had an effi -
cacy of 57% and lanreotide SR effi cacy of 48%. For IGF-
I control, octreotide LAR had an effi cacy of 67% and 
Figure 1. Decision tree – acromegaly treatment in Brazil.
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lanreotide SR 47%. Cabergoline was the dopamine ago-
nist considered in the model, with effi cacy of 37% (13). 
Regarding the association of somatostatin analogues and 
cabergoline, the effi cacy data available combines data 
from both octreotide LAR and lanreotide SR. Because 
of that the same effi cacies (21% for GH and 42% for 
IGF-I normalizations) were used for the association of 
cabergoline with any somatostatin analogue (19).
Regarding drug dosage, initial dose of 20mg of oc-
treotide LAR every 28 days was considered in the 1st 
strategy and 30mg of lanreotide SR every 14 days in the 
2nd strategy. The dose increase considered 30mg of oc-
treotide LAR every 28 days and 60mg of lanreotide SR 
every 14 days (equivalent to 30mg of lanreotide SR 
every 7 days). Cabergoline would be administered 1mg/
week alone or in association with one somatostatin ana-
logue. In case of association, octreotide LAR and lanre-
otide SR doses are the same assumed for dose increase.
Tumor shrinkage was not included in the model. 
Tumor shrinkage occurs in 88,5% and 50,7% of the pa-
tients when treated primarily with octreotide LAR and 
lanreotide SR, respectively (18). When somatostatin 
analogues are used as secondary treatment 47% and 
21% of tumor shrinkage is expected with octreotide 
LAR and lanreotide SR, respectively (18).
Based on the Brazilian Guideline (12), it was assu-
med that if GH control is not achieved after surgery, 
drug therapy would be the next treatment option. Data 
for GH control failure post surgery came from the lite-
rature (7,8,20), with microadenomas not presenting 
GH control after the intervention in 20-30% of the ca-
ses and macroadenomas in 50% of the cases. Conside-
ring that macroadenomas represents around 70% of the 
cases (6), it was estimated in the model that 50% of the 
acromegalic patients are treated with medical therapy 
in case of GH control failure post surgery. This propor-
tion was applied to the incidence of 3 cases per million 
per year, lower estimate, given the diffi cult diagnosis of 
this disease. Considering this incidence, the proportion 
of medical therapy usage and a population of 184.184. 
074 in Brazil in 2005 (DATASUS), the model followed 
a hypothetical cohort of 276 patients diagnosed with 
acromegaly in 2005.
Mortality rate was calculated for the specifi c age 
group of 40-49 years, 0.43% per year in 2005 (21), 
given that mean average of diagnosis may start at 30 
years of age with a 10-year delay. Mortality rate for 
acromegaly was calculated as the double of the general 
mortality rate for the matched age group (0.86% per 
year). When GH level is under control, mortality rate 
decreases back to 0.43% per year in the model. 
Costs
Costs were estimated for the Brazilian Public Health 
Care System (SUS). Unit costs were consulted in the 
Public Health Care databases and resource uses estima-
ted from the Brazilian Guideline (12) for Acromegaly 
and literature (13). Costs were estimated to 2005, 
when lanreotide SR was still available in the Public He-
alth Care System Program of Medicine Dispensation.
Table 1 shows somatostatin analogue costs per pre-
sentation in the Public Health Care System (Negotia-
tion between the producer and the government results 
Table 1. Cost per somatostatin analogue in the Public Health Care System (SUS) for acromegaly treatment , Brazil, 2005 reais (R$).
Somatostatin analogue: octreotide LAR
Dose (mg) Interval (days) Total dose per year (mg) Cost per presentation Cost per mg Total Annual Cost
10 28 130.36 R$ 1,369.62 R$ 136.96 R$ 17,853.98
20 28 260.71 R$ 2,106.97 R$ 105.35 R$ 27,465.86
30 28 391.07 R$ 2,844.37 R$ 94.81 R$ 37,077.35
Somatostatin analogue: lanreotide SR
Dose (mg) Interval (days) Total dose per year (mg) Cost per presentation Cost per mg Total Annual Cost
30 14 782.14 R$ 1,556.01 R$ 51.87 R$ 40,569.75
30 10 1,095.00 R$ 1,556.01 R$ 51.87 R$ 56,797.65
30 7 1,564.30 R$ 1,556.01 R$ 51.87 R$ 81,139.50
Source: Ambulatory Information System (SIA) – DATASUS.
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in medicine prices being lower in the Public Health 
Care System). For the different possible dosages and 
intervals of each somatostatin analogue, an average an-
nual cost per patient was calculated in order to compa-
re economic impact of hypothetical cases, previously to 
the modeling. Comparing an annual treatment of 
20mg/28days of octreotide LAR to another of 
30mg/14days of lanreotide SR, octreotide LAR annual 
cost represents less than half of lanreotide SR cost.
Costs included in the decision analytical model 
were direct medical costs, in ambulatory care. For sen-
sitivity analysis, hospitalization was considered too. 
Component items are medicines, radiotherapy and mo-
nitoring, which includes consultations, GH and IGF-I 
level tests. Monitoring tests specifi c to the somatostatin 
analogues use were glucose, TSH and abdominal ultra-
sound. For the two years follow-up, costing estimated 
8 consultations, 8 IGF-1 level tests, 8 GH level tests 
and 4 ultra-sounds. Glucose and TSH tests would oc-
cur every three months after start use of somatostatin 
analogues. It was assumed that there was no increase of 
the use of resources in case of no response to any treat-
ment, as acromegaly is a chronic disease which requires 
constant medical supervision. For radiotherapy, con-
ventional (linear accelerator) modality for 3 fi elds and 
25 fractions were used for costing. Planning radiothe-
rapy cost was added, summing up a radiotherapy cost 
of R$1,353.03 per patient. Death cases were assumed 
to use, on average, half the resources of survival cases 
(as secondary data were used to model the disease and 
its treatment, it is not known in which point of the time 
along the 2-year time horizon deaths occur. As an as-
sumption, the follow-up of cases resulting in death 
would correspond, on average, to 1 year). 
Table 2 summarizes model parameters, maximum 
and minimum limits adopted in sensitivity analysis.
Once acromegaly is a chronic disease, treatment 
costs are continuous. In the model, costs and outcomes 
refer to the 2-year period. Deaths and life years saved 
(LYS) were computed only to this period.
As model time horizon is short, costs and outco-
mes were not discounted.
RESULTS
Base case
Results are presented in Tables 3 and 4.
Costs are detailed for each strategy in Table 3. To-
tal costs are split by management modality (somatosta-
tin analogue; somatostatin analogue dose increase; 
substitution for cabergoline; association of somatosta-
tin analogue and cabergoline; radiotherapy). For each 
branch of the decision tree there is the respective costs, 
either for treatment(s) or monitoring and the number 
of patients on that branch. Average annual cost per pa-
tient was R$ 27,359 for octreotide LAR and R$ 46,287 
for lanreotide SR.
The incremental cost was negative, - R$ 10,448,324 
(Table 4). There were net savings for octreotide LAR 
when it was the somatostatin analogue used in the tre-
atment of acromegaly. Considering the offi cial ex-
change rate of R$2,34/US$1 in 2005 (Banco Central 
do Brasil), the net savings would be US$ 4,465,096. 
Net savings per patient per year were R$ 18,928 
(US$8,089).
In comparison to lanreotide SR, 12 cases of GH 
and 17 cases of IGF-I elevated would be avoided when 
octreotide LAR was the chosen therapy, resulting in 
0.1 death avoided and 0.2 life year saved (LYS) (Table 
4). With lanreotide SR there would be 2.7 deaths esti-
mated from the model against 2.6 deaths with octreo-
tide LAR. The avoidance of 0.1 death in 2 years would 
yield an increment of over 8% in life years saved for 
octreotide LAR. The life year saved increment calcula-
tion was done as described below:
Life year saved
increment  
Death(s) avoided *
Model time hori= zon (2 years)
Number of  deaths with
octreotide LAR strategy
As the treatment with octreotide LAR is more effi -
cacious according to the meta-analysis available (18) 
and less costly in Brazil, this strategy is dominant when 
compared to the lanreotide SR strategy. The Incremen-
tal Cost-Effectiveness Ratio (ICER) is cost-saving.
Sensitivity analysis 
The following variables were included in sensitivity 
analysis: drug effi cacy, drug dose, somatostatin analo-
gue prices and inclusion of hospitalization by acrome-
galy (Table 5). 
Somatostatin analogue prices varied in sensitivity 
analysis according to CAP (Coefi ciente de Adequação 
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Table 2. Model Parameters.
Parameter Base case Sensitivity analysis Source
Minimum Maximum
Dose
Drug
 octreotide LAR 20 mg / 28 days 20 mg / 28 days 30 mg / 28 days Portaria 471, 24/07/2002; Cook and 
cols. (2004); Freda and cols.(2005)
 lanreotide SR 30 mg / 14 days 30 mg / 14 days 30 mg / 7 days Portaria 471, 24/07/2002; Cook and 
cols. (2004); Freda and cols.(2005)
 cabergoline 1 mg / week 1 mg / week 3,5 mg / week Cozzi and cols. (2004)
Costs1
Drug 2
 octreotide LAR R$ 2,288.82 R$ 2,288.82 R$ 3,089.80 SIA/Datasus; Portaria 471, 24/07/2002 
 lanreotide SR R$ 3,380.82 R$ 3,380.82 R$ 6,761.63 SIA/Datasus; Portaria 471, 24/07/2002 
 cabergoline R$ 127.20 R$ 127.20 R$ 445.20 SIA/Datasus; Portaria 471, 24/07/2002 
Radiotherapy3
 Linear accelerator 
 (per fi eld)
R$ 17.49 – – SIA/Datasus
 Planning R$ 41.28 – – SIA/Datasus
Monitoring3
 Endocrinologist 
 consultation 
 IGF-1
R$ 7.56
R$ 13.38
–
–
–
–
SIA/Datasus
SIA/Datasus
 GH R$ 11.40 – – SIA/Datasus
 Ultra-sound R$ 14.52 – – SIA/DATASUS
 Glucose R$ 1.85 – – SIA/DATASUS
 TSH R$ 7.23 – – SIA/DATASUS
Hospitalization3 – – R$ 709.40 SIH/DATASUS
Surgery4 – – – SIH/DATASUS
Effi cacy
GH (IGF-I) level control
 octreotide LAR 57% (67%) 54% 58% Freda and cols. (2005)
 lanreotide SR 48% (47%) 48% 50% Freda and cols. (2005)
 cabergoline 37% 28% 46% Moore and cols. (2002)
 cabergoline+
 Somatostatin Analogue
21% (42%) 21% 40% Cozzi and cols. (2004)
Incidence 3 / million 3 / million 4 / million Donangelo and cols. (2003)
Mortality rate5 (annual) 0.86% 0.86% 1.72% Donangelo and cols. (2003); SIM/
DATASUS
Proportion of anti-secretory 
medication use 
50% 40% 60% Melmed and cols. (1998)
Proportion of Hospitalization 0 0 1.55% SIH; Demographic Data/DATASUS
1 Reais 2005; 2 Monthly cost; 3 Unit cost; 4 Surgery was not included in the model. The procedure “Hipofi sectomia transesfenoidal com microscópio” is reimbursed by SUS 
(R$2.790,98); 5 Mortality rate calculated between 40-49 years of age; Datasus. Sistema de Informações Hospitalares (SIH), CD-Rom.
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Table 3. Total Costs per treatment and Average Annual Cost per patient by somatostatin analogue, Public Health Care System 
Perspective (SUS), Brazil, reais (R$, 2005).
Somatostatin analogue: octreotide LAR
Management Total costs* per 
treatment(s)**
Total costs* of 
monitoring
Number of 
patients
Average annual 
cost per patient
octreotide LAR R$ 8,652,143 R$ 61,064 157 R$ 27,749
Subsequent dose increase of octreotide LAR R$ 4,858,895 R$ 26,258 68 R$ 35,920
Subsequent substitution for cabergoline R$ 348,285 R$ 6,305 19 R$ 9,331
Subsequent association of octreotide LAR and 
cabergoline
R$ 437,770 R$ 2,621 7 R$ 31,456
Subsequent radiotherapy R$ 699,755 R$ 8,909 25 R$ 14,173
Total R$ 14,996,848 R$ 105,156 276 R$ 27,359
Somatostatin analogue: lanreotide SR
Management Total costs* per 
treatment(s)**
Total costs* of 
monitoring
Number of 
patients
Average annual 
cost per patient
lanreotide SR R$ 10,760,350 R$ 51,423 132 R$ 40,954
Subsequent dose increase of lanreotide SR R$ 10,491,342 R$ 26,740 69 R$ 76,218
Subsequent substitution for cabergoline R$ 904,342 R$ 9,221 28 R$ 16,314
Subsequent association of lanreotide SR and 
cabergoline
R$ 1,325,811 R$ 3,832 10 R$ 66,482
Subsequent radiotherapy R$ 1,964,239 R$ 13,028 37 R$ 26,720
Total R$ 25,446,085 R$ 104,244 276 R$ 46,287
*Total costs corresponding to model time horizon (two years); **Each line of Management, after the respective somatostatin analogue, includes the previous 
treatment(s), according to the Brazilian Guideline for Acromegaly, as described in Figure 1. Time in each treatment is explained in “Material and Methods”.
Table 4. Incremental cost, Disease Impact and Incremental 
Cost-Effectiveness Ratios, Acromegaly Treatment with oct-
reotide LAR versus lanreotide SR, Public Health Care System 
Perspective (SUS), Brazil.
Incremental cost (Net Savings) - R$ 10,448,324*
Cases of elevated GH avoided 12
Cases of elevated IGF-I avoided 17
Deaths avoided 0.1
Life years saved (LYS) 0.2
Incremental cost/Case of elevated GH 
avoided
Cost-saving
Incremental cost/Case of elevated 
IGF-I avoided
Cost-saving
Incremental cost/Death avoided Cost-saving
Incremental cost/LYS Cost-saving
*Corresponding to model time horizon (two years).
de Preços) (22). Octreotide LAR (20 mg) price was 
R$ 2,106.97 in 2005 (23), R$ 2,456.40 in 2006 (23) 
and in 2007 after CAP had a reduction to R$ 2,420.95. 
The same price variation was applied to lanreotide 
SR, since it was not in the Public Health Care System 
after 2006.
None of the variations altered the ICER, which re-
mained cost-saving.
DISCUSSION 
The cost-effectiveness analysis (CEA) of somatostatin 
analogues in the treatment of acromegaly in Brazil sho-
wed that octreotide LAR strategy is dominant when 
compared to lanreotide SR strategy. 
A decision tree was used to model the development 
of the disease and its management. For each treatment 
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Table 5. Sensitivity Analysis, Acromegaly Treatment with octreotide LAR versus lanreotide SR, Public Health Care System Per-
spective (SUS), Brazil.
Variable ICER
Minimum Maximum
Incidence 3/million 4/million Cost-saving Cost-saving
Mortality rate 2 x GPMR* 4 x GPMR* Cost-saving Cost-saving
Drug
Effi cacy**
octreotide LAR 54% 58% Cost-saving Cost-saving
lanreotide SR 48% 50% Cost-saving Cost-saving
cabergoline 28% 46% Cost-saving Cost-saving
cabergoline+somatostatin 
analogue
21% 40% Cost-saving Cost-saving
Dose
octreotide LAR 20 mg/28 days 30 mg/28 days Cost-saving Cost-saving
lanreotide SR 30 mg/14 days 30 mg/7 days Cost-saving Cost-saving
cabergoline 1 mg/week 3.5 mg/week Cost-saving Cost-saving
CAP*** (Drug price)
octreotide LAR R$ 2,420.95 Cost-saving
lanreotide SR R$ 1,787.89 Cost-saving
Rate Cost
Hospitalization 1.55% R$ 709.40 Cost-saving
* General Population Mortality Rate (40-49 years of age); ** GH control; *** Coefi ciente de Adequação de Preços.
option, the respective branch represented the period of 
time on that, the number of patients and the costs in-
curred until response is accomplished or not. Probabi-
lities of death also changed to GH elevated cases 
controlled or not. Surgery was not considered in case 
of non response to association of a somatostatin analo-
gue and dopamine agonist and was not initially inclu-
ded in the model. The absence of initial transsphenoidal 
surgery does not affect the results of the analysis. The 
costs for surgery will be the same for both strategies 
before drug therapy is introduced. Surgery can infl uen-
ce somatostatin analogue effi cacy in regards to bioche-
mical control when the medical therapy is prescribed 
after surgery (second line therapy). Because of that, in 
the model, data regarding somatostatin analogues effi -
cacy as secondary treatment also included patients who 
had undergone surgery (18). As we analyzed the incre-
mental costs and outcomes between octreotide LAR and 
lanreotide SR, previous events to the decision node will 
be the same for both somatostatin analogue strategies.
The model was based on a local guideline, as re-
commended by SUS. Non-adherence in clinical practi-
ce to the guideline would affect both the structure and 
results of the model. Effi ciency of guideline implemen-
tation can be very heterogeneous (24) so no assump-
tion was made in the model. Another issue was that the 
Brazilian Guideline for the treatment of Acromegaly 
differs from international guidelines, which recom-
mend GH receptor antagonist after inadequate respon-
se to a somatostatin analogue (1; 25). GH receptor 
antagonist is not considered as a treatment option in 
the Brazilian Guideline (12).
Although the 2-year time horizon considered in the 
model was short, it was suffi cient to follow response or 
not to the somatostatin analogues. The analysis also in-
tended to be as close as possible to changes in the Public 
Health Care System, so the hypothetical cohort diagno-
sed in 2005 was followed for the period that both soma-
tostatin analogues were offered by SUS, with prices still 
available in SIA (Ambulatory Information System).
The concern about replicating the reality of Public 
Health Care System into the model is due to the fact 
that this analysis is a post inclusion health economic eva-
1460 Arq Bras Endocrinol Metab 2008;52/9
CEA of Somatostatin Analogues in Acromegaly
Valentim et al.
c
o
p
yr
ig
h
t©
 A
BE
&
M
 t
o
d
o
s 
o
s 
d
ire
ito
s 
re
se
rv
a
d
o
s
luation. In the literature, it is rare to fi nd economic eva-
luations as tools to monitor health technologies already 
incorporated and to guide their continuity (26). This 
cost-effectiveness analysis contributes to the study of the 
disease and economic impacts of acromegaly in Brazil as 
well as to the assessment of the reimbursement of a spe-
cifi c technology (somatostatin analogue) by SUS.
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